OBJECTIVES: To evaluate the efficacy of treatment with ranibizumab in a sample of Greek patients with nAMD. METHODS In this observational, non-interventional, retrospective study, 194 cases with nAMD were enrolled from the Ophthalmology Department of “Attikon” hospital. Patients treated with ranibizumab for at least one year in one eye under routine clinical practice, and had at least one follow-up visit, were considered eligible. Patients participating in another study and/or were receiving pharmaceutical product containing VEGF inhibitors were excluded. Primary endpoints were the mean change in Best Corrected Visual Acuity (BCVA), and in Central retinal thickness (CRT), assessed by Optical Coherence Tomography. RESULTS The average BCVA score per eye at baseline was 0.284 in decimal points (Snellen equivalent≈ 20/84; ETDRS letters≈ 57.7), which improved at final visit (≈14 months after baseline) reaching 0.336 (Snellen equivalent≈ 20/60; ETDRS letters≈ 61.3), i.e. 6,33% or approximately 3.7 ETDRS letters improvement (p<0.001, r=0.317) with 4.9 ranibizumab injections overall (4.3 injections/year). CRT similarly improved, as it decreased by 28.4%, from 290.31 to 207.77 μm (p<0.001, r=0.683). An extra ranibizumab injection per eye per year, increased the odds of an at least 0.1 increase in BCVA from baseline to last visit by 20.8% (95%CI 1.068-1.366), and an at least 0.2 increase by 15.7% (95%CI 1.013-1.322). CONCLUSIONS Ranibizumab provides significant benefit in patients with nAMD under routine clinical practice by improving BCVA and reducing CRT, benefit which may be more important in a more frequent dosing regimen.